Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AGY.LSE
- Price
- 9.00
- Stock movement down
- -0.30 (-3.23%)
- Company name
- Allergy Therapeutics
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 552.73M
- Ent value
- 611.17M
- Price/Sales
- 5.07
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 64.23%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-25
DIVIDENDS
AGY.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.07 |
| Price to Book | - |
| EV to Sales | 5.61 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.14B |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 21.68M |
| Net receivables | 8.62M |
| Total current assets | 42.16M |
| Goodwill | 3.30M |
| Intangible assets | 1.21M |
| Property, plant and equipment | 23.32M |
| Total assets | 72.97M |
| Accounts payable | 14.23M |
| Short/Current long term debt | 45.97M |
| Total current liabilities | 26.43M |
| Total liabilities | 80.12M |
| Shareholder's equity | -7.15M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.50 |
| Daily high | 9.40 |
| Daily low | 8.50 |
| Daily Volume | 932K |
| All-time high | 9.35 |
| 1y analyst estimate | 13.00 |
| Beta | 0.80 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AGY.LSE | S&P500 | |
| Current price drop from All-time high | -3.74% | -1.80% |
| Highest price drop | -31.82% | -19.00% |
| Date of highest drop | 11 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -6.67% | -2.73% |
| Avg time to new high | 5 days | 6 days |
| Max time to new high | 106 days | 89 days |
COMPANY DETAILS
Marketcap
552.73M
Marketcap category
Small-cap
Description
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
Employees
0
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found